News

Teva news, press releases, and media contact information

Press Releases
Keyword Search
 
  
For all global news, visit our corporate site.
10/10/2017Teva to Report Third Quarter 2017 Financial Results on November 2, 2017JERUSALEM--(BUSINESS WIRE)--Oct. 10, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its th... 
10/04/2017Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mLJERUSALEM--(BUSINESS WIRE)--Oct. 4, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today commented that any launch by ... 
09/25/2017Teva Announces Reintroduction of Generic Depo-Provera® in the United StatesJERUSALEM--(BUSINESS WIRE)--Sep. 25, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the reintroduction of the ... 
09/19/2017Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO® (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United StatesJERUSALEM & SAN FRANCISCO--(BUSINESS WIRE)--Sep. 19, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Nuvelution Phar... 
09/18/2017New Initiative Creates Scalable Solutions to Improve Care of Patients with Multiple Chronic ConditionsTeva and Mount Sinai Health System pursue new models to reduce cost and complexity of care JERUSALEM & NEW YORK--(BUSINESS WIRE)--Se... 
09/18/2017Teva Announces Sale of Remaining Assets in Specialty Global Women’s Health Portfolio for $1.38 BillionCompany executes sale agreements for planned divestiture of global women’s health business to generate total proceeds of $2.48 billion ... 
09/14/2017Teva to Present Data for AUSTEDO® (deutetrabenazine) Tablets and Other Research at the 2017 Psych CongressJERUSALEM--(BUSINESS WIRE)--Sep. 14, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the presentation o... 
09/12/2017Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)JERUSALEM--(BUSINESS WIRE)--Sep. 12, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the U.S. Food and Drug Admi... 
09/11/2017Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgicalCompany takes first step in planned divestment of non-core assets JERUSALEM--(BUSINESS WIRE)--Sep. 11, 2017-- Teva Pharmaceutical In... 
09/11/2017Teva Names Kåre Schultz as President and Chief Executive OfficerBrings 30 Years of Global Pharmaceutical and Healthcare Experience, Including Leadership Positions at Lundbeck and Novo Nordisk ... 
08/30/2017Teva Announces FDA Approval of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in AdultsAUSTEDO® is the first and only FDA-approved product to treat both tardive dyskinesia in adults and chorea associated with Huntington’s d... 
08/18/2017Teva Announces Exclusive Launch of Generic Axiron® in the United StatesJERUSALEM--(BUSINESS WIRE)--Aug. 18, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of gen... 
08/07/2017Teva Announces FDA Approval of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation AerosolMaintenance Treatment Option Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE... 
08/03/2017Teva Reports Second Quarter 2017 Financial ResultsRevenues of $5.7 billion GAAP EPS loss of $5.94 Non-GAAP EPS of $1.02 2017 ... 
07/31/2017Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin® (trastuzumab)INCHEON, Republic of Korea & JERUSALEM--(BUSINESS WIRE)--Jul. 31, 2017-- Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE... 
07/28/2017Teva Announces Launch of Generic Epiduo® in the United StatesJERUSALEM--(BUSINESS WIRE)--Jul. 28, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of gen... 
07/24/2017Teva Announces the Launch of Generic Vagifem® in the United StatesJERUSALEM--(BUSINESS WIRE)--Jul. 24, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a ge... 
07/13/2017Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of ShareholdersJERUSALEM--(BUSINESS WIRE)--Jul. 13, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that all proposals were approved a... 
07/11/2017Teva to Report Second Quarter 2017 Financial Results on August 3, 2017JERUSALEM--(BUSINESS WIRE)--Jul. 11, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its se... 
07/11/2017Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA NeurologyData support overnight conversion from tetrabenazine to AUSTEDO™ for the treatment of chorea associated with Huntington disease JERU... 
06/29/2017Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab)INCHEON, South Korea & JERUSALEM--(BUSINESS WIRE)--Jun. 29, 2017-- Celltrion, Inc., a global biopharmaceutical company, and Teva Pharmac... 
06/09/2017Teva Announces Exclusive Launch of Generic Pataday® in the United StatesJERUSALEM--(BUSINESS WIRE)--Jun. 9, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of gene... 
06/07/2017Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine PreventionStatistically and clinically significant results demonstrate fremanezumab's efficacy and safety, including unique quarterly subcutaneous... 
06/06/2017Teva to Present at the Jefferies 2017 Global Healthcare ConferenceJERUSALEM--(BUSINESS WIRE)--Jun. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at t... 
05/31/2017Teva Announces Positive Results for Phase III Study of Fremanezumab for the Prevention of Chronic MigraineChronic migraine study met all primary and secondary endpoints in both monthly and quarterly dosing regimens JERUSALEM--(BUSINESS WI... 
05/17/2017Teva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International ConferenceNew Data To Be Presented Show Reduction in ER Visits and Hospitalizations in Patients with Varying Levels of Disease Severity Fo... 
05/17/2017Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual MeetingData contribute to growing body of evidence supporting the development of deutetrabenazine for the treatment of tardive dyskinesia ... 
05/15/2017Teva Announces Launch of Generic Glumetza® in the United StatesJERUSALEM--(BUSINESS WIRE)--May 15, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of gene... 
05/11/2017Teva Reports First Quarter 2017 Financial ResultsJERUSALEM--(BUSINESS WIRE)--May 11, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the q... 
04/27/2017Teva Announces Publication of ARM-TD Study Results in Neurology® for the Investigational Use of Deutetrabenazine in Tardive DyskinesiaJERUSALEM--(BUSINESS WIRE)--Apr. 27, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced the publication of ... 
04/26/2017Teva Announces Launch of Generic Vytorin® in the United StatesJERUSALEM--(BUSINESS WIRE)--Apr. 26, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of gene... 
04/20/2017Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and SalmeterolFirst and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S. JERUSALEM--(BUSINESS WIRE)--Ap... 
04/19/2017Teva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of NeurologyData to be presented spans central nervous system disorders, including tardive dyskinesia, multiple sclerosis, Huntington’s disease, and... 
04/06/2017Teva to Report First Quarter 2017 Financial Results on May 11, 2017JERUSALEM--(BUSINESS WIRE)--Apr. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fir... 
04/03/2017Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s DiseaseApproval represents the first new treatment option for chorea associated with Huntington’s disease in nearly a decade JERUSALEM--(BU... 
03/16/2017Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United StatesJERUSALEM--(BUSINESS WIRE)--Mar. 16, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of the ... 
03/13/2017Teva to Present at the Barclays Global Annual Healthcare ConferenceJERUSALEM--(BUSINESS WIRE)--Mar. 13, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at ... 
03/06/2017Teva to Present at the Cowen & Company 37th Annual Healthcare ConferenceJERUSALEM--(BUSINESS WIRE)--Mar. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at t... 
03/01/2017Teva Announces Launch of Generic Pristiq® in the United StatesJERUSALEM--(BUSINESS WIRE)--Mar. 1, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of gene... 
02/28/2017Teva Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive DyskinesiaJERUSALEM--(BUSINESS WIRE)--Feb. 28, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced the U.S. Food and D... 
02/15/2017Teva Files 2016 Annual Report on Form 20-FJERUSALEM--(BUSINESS WIRE)--Feb. 15, 2017-- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva... 
02/13/2017Teva Reports Full Year and Fourth Quarter 2016 Financial ResultsJERUSALEM--(BUSINESS WIRE)--Feb. 13, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the ... 
02/06/2017Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez VigodmanDr. Sol J. Barer Named Chairman of the Board JERUSALEM--(BUSINESS WIRE)--Feb. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE an... 
02/02/2017Teva Confirms Generic Victoza® Patent Challenge in the United StatesJERUSALEM--(BUSINESS WIRE)--Feb. 2, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that it has filed a... 
02/01/2017Teva to Report Fourth Quarter 2016 Financial Results on February 13, 2017JERUSALEM--(BUSINESS WIRE)--Feb. 1, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fou... 
01/30/2017Teva Confirms District Court Decision in COPAXONE® 40 mg/mL Patent TrialJERUSALEM--(BUSINESS WIRE)--Jan. 30, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed the U.S. District ... 
01/30/2017Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of AsthmaApprovals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coor... 
01/18/2017Teva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets [CII] Formulated with Proprietary Abuse Deterrence TechnologyVANTRELA ER label describes the product’s abuse-deterrent properties against abuse in the three most common routes—oral, intranasal an... 
01/06/2017Teva to Present at the 35th Annual J.P. Morgan Healthcare ConferenceJERUSALEM--(BUSINESS WIRE)--Jan. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 35th A... 
01/06/2017Teva Provides 2017 Financial OutlookJERUSALEM--(BUSINESS WIRE)--Jan. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) provides its current outlook for non... 
01/05/2017Teva to Host 2017 Business Outlook Conference Call and Webcast on January 6, 2017JERUSALEM--(BUSINESS WIRE)--Jan. 5, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will host a conferenc... 
  Teva Stories
09/25/2017
Teva Continues to Advance Care for Society’s Health and Wellbeing; 2016 Social Impact Report Released

In 2016, Teva engaged more than 300,000 people in 35 countries in programs aimed to help and empower patients as they deal with their illnesses.


04/06/2017
Teva Generics Enters 4th Year as Premier Pharmaceutical Partner of the Iconic Blue Cross Broad Street Run in Philadelphia!

Teva Generics is proud to partner with Philadelphia Parks and Recreation for the fourth consecutive year as the Premier Pharmaceutical Partner of the Blue Cross Broad Street Run!


Biography Photo
03/22/2017
Teva Generics Launches Birth Control for Her Website
Did you know that Teva has nearly 50 oral contraceptives in its generics portfolio in the U.S.? And while you’ve probably seen the statistic that 1 of every 6 prescriptions filled in the U.S. is a Teva product, you might not know that 1 of every 2 contraceptive prescriptions in the U.S. is filled with a Teva product.
Biography Photo
02/15/2017
Andy Boyer, GGM North America President & CEO Speaks on Association for Accessible Medicines (AAM) Industry-CEO Panel
Today Andrew Boyer, Teva's‎ President & CEO of Global Generic Medicines, North America spoke on a panel of industry CEOs during the annual meeting of the Association for Accessible Medicines (AAM). The AAM, formerly known as the Generic Pharmaceutical Association (GPhA), hosted leadership from Teva, Momenta Pharmaceuticals, Lupin Limited and Dr. Reddy's Laboratories during the “CEO Unplugged” panel moderated by ABC News reporter John Donvan. Andy highlighted the importance of the generic pharmaceutical industry in the larger context of U.S. healthcare, and the importance of sharing our story of value and access to American patients.
Biography Photo
01/26/2017
Teva Announces 2017-18 Community Partnership Program Organizations
Teva Pharmaceuticals today announced the U.S. organizations selected as part of Teva’s 2017-18 Community Partnership Program. Now in its fourth year, this exciting Teva program provides charitable funding and employee volunteers to qualified local organizations that support patients and their caregivers and Science, Technology, Engineering and Mathematics (STEM) programs in geographic areas where Teva has a business presence.
Biography Photo
11/10/2016
AIFL Rings Opening Bell at NYSE; Teva's Keren Haruvi Honored
Today at the 2016 Israel Day at the New York Stock Exchange – in conjunction with the American-Israel Friendship League, Keren Haruvi, SVP, GGM Business Development, Teva – participated in ringing the Opening Bell.
Biography Photo
11/02/2016
TevaUSA Named a Best Employer for Healthy Lifestyles
Our health and wellness benefits just reached “award winning” status, enabling us to improve health not only for patients worldwide; but, for our employees and their families too!
Biography Photo
06/20/2016
Teva CEO Erez Vigodman speaks at 2016 SelectUSA Investment Summit
On June 20 at the 2016 SelectUSA Investment Summit in Washington D.C., Erez Vigodman, President & CEO, Teva Pharmaceuticals, spoke to investors, representatives of U.S. economic development organizations, U.S. state and local governments officials and others, about Teva’s critical role in delivering value to the U.S. healthcare system and economy.
Biography Photo
04/01/2016
Teva takes on a tornado
When a natural disaster struck in Virginia, Teva employees didn’t wait to be asked—they jumped up to help.
Biography Photo
03/02/2016
Teva’s Community Partnership Program: Making an Impact Together in 2016
This exciting Teva program provides charitable funding and employee volunteers to qualified local organizations that support patients and their caregivers in geographic areas where Teva has business presence.
Biography Photo
12/14/2015
Rolling up our sleeves to help kids get wheels
We’re known for making medicines at Teva. And lately, we’ve also been building…bicycles? Here’s why.
Biography Photo
11/06/2015
TAPI Vice President named to leading industry board
We know our Teva leaders have unmatched expertise—and our industry associations recognize it too. The Drug, Chemical & Associated Technology Association named Kerri McCullough Wood, VP and Head of Global TAPI sales, to their Board of Directors this fall.
Biography Photo
10/23/2015
Homeless but not friendless: Teva's Cincinnati women help homeless young adults
On Tuesday, October 13, the Women@Teva Employee Resource Group's Community Outreach team had their first event at Lighthouse Youth Services and The Sheakley Center in Cincinnati, Ohio. Nineteen women volunteered their time to serve homeless young adults ranging in age from 18-24.
Biography Photo
10/14/2015
Rutgers and Teva Join Forces in Support of Pharmaceutical Industry Fellowship Program
Teva Regulatory Affairs is excited to be part of the Pharmaceutical Industry Fellowship Program at Rutgers University. We believe Teva offers a unique opportunity to gain experience in both generic and branded regulatory affairs in our facilities located in the suburban Philadelphia area.
Biography Photo
09/10/2015
Teva Announces Newly Named Grant Program and 2015 Awardees at Boston Symposium
Teva recognizes that great medicines begin with great science. Teva has re-established the Teva Pharmaceutical Scholars Grant Program, now known as the Teva Pharmaceuticals Marc A. Goshko Memorial Grant Program.
Biography Photo
09/09/2015
Call for Entries! Apply for Teva's 2016 Community Partnership Program
Each year, Teva selects patient- and caregiver-focused organizations in areas where we have a significant business presence to be part of our Community Partnership program. These organizations receive a charitable donation from Teva, and they provide volunteer opportunities for our employees in those regions.
Biography Photo
07/13/2015
Summer showers honors on US Generics
At Teva, we try to make a difference and improve access to good health care every day. In June and July, Teva was honored with two major industry awards for doing just that.
Biography Photo
06/17/2015
Pride Month at Teva
Our Pride Month theme is “The Courage to Be.” It’s a way of saying that we at Teva welcome everyone and stand for full self-expression in the workplace.
Biography Photo
05/21/2015
Teva takes steps to fight hate
Teva is committed to promoting a more diverse and inclusive society—not only within our organization but throughout the communities where we live and work—and we’re taking (literal) steps to show it!
Biography Photo
05/15/2015
Michelle Cuccia recognized during HBA Rising Star luncheon
On May 14, Teva’s own Michelle Cuccia, Marketing Vice President – Growth Markets, was honored at the annual Healthcare Businesswomen’s Association (HBA) Woman of the Year luncheon.
Biography Photo
05/11/2015
Teva’s Northeast Pain Care Team brings fun to kids
Sometimes you never know where you’ll find the path to help make people’s lives better.
Biography Photo